BRPI0517200A - combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento - Google Patents

combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento

Info

Publication number
BRPI0517200A
BRPI0517200A BRPI0517200-4A BRPI0517200A BRPI0517200A BR PI0517200 A BRPI0517200 A BR PI0517200A BR PI0517200 A BRPI0517200 A BR PI0517200A BR PI0517200 A BRPI0517200 A BR PI0517200A
Authority
BR
Brazil
Prior art keywords
antibiotic
present
resistant
provides
amicacin
Prior art date
Application number
BRPI0517200-4A
Other languages
English (en)
Inventor
Manu Chaudhary
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of BRPI0517200A publication Critical patent/BRPI0517200A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMBINAçõES DE ANTIBIóTICOS, PROCESSOS DE PREPARAçãO DE UMA COMBINAçãO DE ANTIBIóTICOS E MéTODO DE TRATAMENTO. A presente invenção refere-se a nova composição farmacêutica, método de tratamento de infecções e também processo de preparação da composição. As complicações infecciosas são causas importantes da morbidez e mortalidade. Pneumonia adquirida em hospital (HAP) permanece a mais severa infecção nosocómica em unidades de terapia intensiva. Beta-lactamas isoladamente são sempre consideradas inadequadas quando P. aeruginosa e/ou S. aerus resistente a meticilina são indicadas como patógenos ou copatógenos. A presente invenção fornece a terapia empírica desejada para o controle de todas as infecções bacterianas. A presente invenção fornece produtos de combinação de antibióticos para o fornecimento de pelo menos dois antibióticos diferentes, por meio de forma de dosagem parenteral que compreende antibiótico inibidor da síntese de proteínas que é amicacin ou seu sal de sulfato e antibiótico não inibidor da síntese de proteínas que é cefepima ou seu sal de cloridrato. A presente invenção fornece solução total contra P. aeruginosa ou Acinetobacter spp. multi-resistentes e/ou S. aureus resistente a meticilina e é útil para administração intramuscular ou intravenosa como antibiótico para pacientes hospitalizados com infecções sérias ou agudas. As composições farmacêuticas descritas no presente possuem normalmente a menor nefrotoxicidade e possuem melhor eficácia e segurança de combinação de cefepima mais amicacin.
BRPI0517200-4A 2004-12-17 2005-12-16 combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento BRPI0517200A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2510DE2004 2004-12-17
PCT/IN2005/000415 WO2006064516A1 (en) 2004-12-17 2005-12-16 Antibiotic combinations for providing total solution to the treatment of infections

Publications (1)

Publication Number Publication Date
BRPI0517200A true BRPI0517200A (pt) 2008-09-30

Family

ID=35811679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517200-4A BRPI0517200A (pt) 2004-12-17 2005-12-16 combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento

Country Status (13)

Country Link
US (1) US8178501B2 (pt)
EP (1) EP1861110B1 (pt)
JP (1) JP2008524204A (pt)
KR (1) KR100900208B1 (pt)
CN (1) CN101076342A (pt)
AU (1) AU2005315140B2 (pt)
BR (1) BRPI0517200A (pt)
CA (1) CA2591157C (pt)
MX (1) MX2007007235A (pt)
NZ (1) NZ555076A (pt)
UA (1) UA91205C2 (pt)
WO (1) WO2006064516A1 (pt)
ZA (1) ZA200704392B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540515A (ja) * 2005-05-13 2008-11-20 ヴィーナス・レメディーズ・リミテッド 嚢胞性線維症を含む重症感染症の処置および管理
WO2007086013A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising of ceftazidime, tazobactam and linezolid
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
BRPI0913709A2 (pt) * 2008-09-18 2015-10-13 Manu Chaudhary "formulação farmacêutica"
RU2391105C1 (ru) * 2009-01-11 2010-06-10 Игорь Михайлович Борисов Способ лечения пневмонии
WO2012084272A1 (en) * 2010-12-23 2012-06-28 Intercell Ag Oprf/i agents and their use in hospitalized and other patients
US10723764B2 (en) 2011-11-21 2020-07-28 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and methods of use thereof
US9580472B2 (en) 2011-11-21 2017-02-28 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and methods of use thereof
EP2953626A1 (en) * 2013-02-06 2015-12-16 Astrazeneca AB Combination therapy for the treatment of nosocomial pneumonia
NZ719215A (en) * 2013-10-22 2020-04-24 Wockhardt Ltd Pharmaceutical compositions comprising antibacterial agents
CN106220647A (zh) * 2016-07-25 2016-12-14 海南汤臣史克生物科技有限公司 一种头孢硫脒化合物及其制剂和制备方法
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
GB2595513B (en) * 2020-05-29 2023-03-29 Act Therapeutics Ltd Treatment of infections
CN111904929B (zh) * 2020-06-28 2023-02-07 江苏吴中医药集团有限公司 一种硫酸阿米卡星注射液及其制备方法
CN116116308B (zh) * 2022-12-16 2025-10-28 上海楼哒物流技术中心 一种医用配液机及其配液方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH16771A (en) * 1978-04-19 1984-02-22 Ciba Geigy Ag Synergistic mixtures of cepsulodin sodium and an aminoglycoside
FR2546406A1 (fr) * 1983-05-27 1984-11-30 Michaux Jean Preparation medicale a usage veterinaire, en particulier pour les ulceres linguaux
US4775533A (en) * 1987-02-24 1988-10-04 Erbamont, Inc. Reconstitution of dry fill cyclophosphamide
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
CA2101571A1 (en) * 1992-09-08 1994-03-09 Elizabeth A. Garofalo Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof
KR0139235B1 (ko) * 1994-01-29 1998-04-28 조세현 정형외과용 세멘트 비드조성물 및 그의 제조방법
CZ75597A3 (en) * 1995-07-17 1997-08-13 Fraunhofer Ges Forschung Biologically active, metal containing ribonucleotide polypeptide, process of its preparation and pharmaceutical composition containing thereof
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
AU1572101A (en) * 1999-11-08 2001-06-06 Pharmacia & Upjohn Company Admixture of linezolid and other antibacterial agents
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US20070167380A1 (en) * 2002-04-03 2007-07-19 Rahul Dabre Taste masked compositions of erythromycin a and derivatives thereof
JP3976257B2 (ja) * 2002-09-17 2007-09-12 栄研化学株式会社 蛋白質の安定化方法
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Also Published As

Publication number Publication date
JP2008524204A (ja) 2008-07-10
EP1861110B1 (en) 2014-03-26
EP1861110A1 (en) 2007-12-05
AU2005315140B2 (en) 2010-05-27
KR100900208B1 (ko) 2009-06-02
AU2005315140A1 (en) 2006-06-22
WO2006064516A1 (en) 2006-06-22
US8178501B2 (en) 2012-05-15
ZA200704392B (en) 2008-08-27
KR20070063036A (ko) 2007-06-18
CA2591157C (en) 2012-06-12
NZ555076A (en) 2010-01-29
US20090318378A1 (en) 2009-12-24
UA91205C2 (ru) 2010-07-12
CN101076342A (zh) 2007-11-21
MX2007007235A (es) 2007-10-19
CA2591157A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
BRPI0517200A (pt) combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento
DOP2020000058A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas
Sharma et al. Comparative study between penicillin and ampicillin
TWI327573B (en) 6-11 bicyclic ketolide derivatives
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
WO2008036761A3 (en) Anti-microbial defensin-related peptides and methods of use
BR112015024939A2 (pt) composto, diastereoisômero ou epímero de um composto, composição farmacêutica, uso de um composto, processo para a preparação de um composto, e, método para tratamento de uma infecção
BR112015024871A2 (pt) composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção
AR073917A1 (es) Sinergismo antibiotico
MX2011002874A (es) Novedosas formulaciones de carbapenem aminoglicosido como una sola unidad.
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
MX2023012943A (es) Compuesto antibacteriano.
US10314813B2 (en) Antimicrobial compositions for Clostridium difficile
WO2007044927A3 (en) 6, 11-bridged tricyclic macrolides
TW200635600A (en) Tetracyclic bicyclolides
Rahman et al. Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia
Castagnola et al. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer
WO2010012381A8 (en) Streptospirole derivatives
BR112018071101A2 (pt) derivados bioaromáticos antibacterianos com substituição de oxetana-3-iloxi
Winslow Cefazolin and Ertapenem as Salvage Therapy in Methicillin-Susceptible Staphylococcus aureus Bacteremia
Huband et al. In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
CN1836659A (zh) 阿洛西林/舒巴坦抗菌组合药物
ITMI20000262A1 (it) Uso del tiamfenicolo per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni da staphylococci vancomicino-in
Abd The role of combination of Meropenem with gentamicin in reducing emergence of antibiotic resistance in some highly resistant staphylococcus species in vitro
BHARDWAJ et al. Newer antimicrobials for resistant gram-positive infections

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.